Literature DB >> 17064435

Bipolar depression: diagnostic and treatment considerations.

Michael E Thase1.   

Abstract

Bipolar affective disorder is a recurrent, disabling, and potentially lethal illness that typically begins early in life. Although the disorder is defined by the manic and hypomanic episodes, for most people the depression episodes are the more virulent aspect of the illness. Specifically, the depressive episodes are more numerous, last longer, and are more difficult to treat than the manias, and depression is the principal cause of the illness's increased mortality due to suicide. For people with early-onset depression, predictors of subsequent bipolarity include a family history, psychotic features, and reverse neurovegetative features. Initial episodes of depression are commonly misdiagnosed, which often delays initiation of appropriate therapy and increases the likelihood of treatment with antidepressants alone. Unfortunately, the correct diagnosis is often not made until there has been a treatment-emergent affective switch. There are no treatments specifically approved for bipolar disorder in youth and, among antidepressants, only fluoxetine has received approved. When bipolarity is suspected, treatment with mood stabilizers, both conventional (i.e., lithium, valproate, and carbamazapine) and more recently classified (lamotrigine) and atypical antipsychotics should be prioritized. When antidepressants are indicated in combination with mood stabilizers, first choice options include bupropion and the selective serotonin reuptake inhibitors. Studies of adults indicate that several forms of focused psychotherapy may improve longer term outcomes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17064435     DOI: 10.1017/S0954579406060585

Source DB:  PubMed          Journal:  Dev Psychopathol        ISSN: 0954-5794


  10 in total

1.  Influence of family history of major depression, bipolar disorder, and suicide on clinical features in patients with major depression and bipolar disorder.

Authors:  Alessandro Serretti; Alberto Chiesa; Raffaella Calati; Sylvie Linotte; Othman Sentissi; Konstantinos Papageorgiou; Siegfried Kasper; Joseph Zohar; Diana De Ronchi; Julien Mendlewicz; Daniela Amital; Stuart Montgomery; Daniel Souery
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-05-09       Impact factor: 5.270

2.  Characteristics of depression among offspring at high and low familial risk of bipolar disorder.

Authors:  Rasim Somer Diler; Tina R Goldstein; Danella Hafeman; Brian Thomas Rooks; Dara Sakolsky; Benjamin I Goldstein; Kelly Monk; Mary Beth Hickey; David Axelson; Satish Iyengar; Boris Birmaher
Journal:  Bipolar Disord       Date:  2017-06-14       Impact factor: 6.744

3.  Effectiveness and safety of the combination of fluoxetine and olanzapine in outpatients with bipolar depression: an open-label, randomized, flexible-dose study in Puerto Rico.

Authors:  Jorge M Tamayo; Virginia K Sutton; Manuel A Mattei; Barbara Diaz; Hassan H Jamal; Eduard Vieta; Carlos A Zarate; Ileana Fumero; Mauricio Tohen
Journal:  J Clin Psychopharmacol       Date:  2009-08       Impact factor: 3.153

Review 4.  Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress.

Authors:  Michael D Kritzer; Nicholas A Mischel; Jonathan R Young; Christopher S Lai; Prakash S Masand; Steven T Szabo; Sanjay J Mathew
Journal:  Ann Clin Psychiatry       Date:  2022-02       Impact factor: 2.691

5.  The Risk of Treatment-Emergent Mania With Methylphenidate in Bipolar Disorder.

Authors:  Alexander Viktorin; Eleonore Rydén; Michael E Thase; Zheng Chang; Cecilia Lundholm; Brian M D'Onofrio; Catarina Almqvist; Patrik K E Magnusson; Paul Lichtenstein; Henrik Larsson; Mikael Landén
Journal:  Am J Psychiatry       Date:  2016-10-03       Impact factor: 18.112

6.  Positron emission tomography quantification of serotonin-1A receptor binding in medication-free bipolar depression.

Authors:  Gregory M Sullivan; R Todd Ogden; Maria A Oquendo; J S Dileep Kumar; Norman Simpson; Yung-yu Huang; J John Mann; Ramin V Parsey
Journal:  Biol Psychiatry       Date:  2009-03-17       Impact factor: 13.382

7.  Adjunctive Behavioral Activation for the Treatment of Bipolar Depression: A Proof of Concept Trial.

Authors:  Lauren M Weinstock; Caitlin Melvin; Mary K Munroe; Ivan W Miller
Journal:  J Psychiatr Pract       Date:  2016-03       Impact factor: 1.325

8.  A bibliometric analysis of bipolar affective disorders using density-equalizing mapping and output benchmarking.

Authors:  B H Vogelzang; C Scutaru; S Mache; K Vitzthum; B Kusma; O Schulte-Herbrüggen; D A Groneberg; D Quarcoo
Journal:  Indian J Psychiatry       Date:  2012-10       Impact factor: 1.759

Review 9.  Challenges in the diagnosis and treatment of pediatric bipolar depression.

Authors:  Kiki Chang
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

10.  Dysregulation of leukocyte gene expression in women with medication-refractory depression versus healthy non-depressed controls.

Authors:  Eli Iacob; Kathleen C Light; Scott C Tadler; Howard R Weeks; Andrea T White; Ronald W Hughen; Timothy A Vanhaitsma; Lowry Bushnell; Alan R Light
Journal:  BMC Psychiatry       Date:  2013-10-21       Impact factor: 3.630

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.